Literature DB >> 8825133

Estrogen receptors, progesterone receptors, and cell proliferation in human breast cancer.

M A Fanelli1, L M Vargas-Roig, F E Gago, O Tello, R Lucero De Angelis, D R Ciocca.   

Abstract

The breast is a target organ for estrogens and progesterone. These hormones control several functions of the normal and abnormal mammary epithelium including cell proliferation. Most of the actions of estrogens and progesterone are mediated via specific steroid receptors, and one would expect that proliferating cells should contain estrogen receptors (ER) and/or progesterone receptors (PR). However, the correlation between receptor expression and cell proliferation is still controversial. In the present study we have examined 29 human breast cancer samples; in 17 of them we evaluated the simultaneous ER and PR localization with that of proliferating cell nuclear antigen (PCNA) and silver-stained nucleolar organizer regions (AgNORs) in a cell-by-cell study. We found that in almost 50% of the tumor biopsies examined, the cells expressing ER were significantly associated with elevated cell proliferation. In another group (38%) there were not significant differences between ER expression and cell proliferation. In only one of the samples (6%) the cells expressing ER showed lower cell proliferation. The study also revealed that in 44% of the tumors the PR expressing cells were associated with elevated cell proliferation. In a second group the PR expression was not significantly associated with cell proliferation (33% of the cases). Finally, in 22% of the samples the cells carrying PR showed lower cell proliferation. We also detected lower ER immunoreactivity in 30% of the breast cancer biopsies with one of the monoclonal antibodies against ER (antibody 1D5 directed against the A/B domain). This group of tumors was PR-negative (or very weakly positive) and had high proliferation. The presence of tumors with 'abnormal' ER proteins and displaying ER/PR significantly associated with elevated cell proliferation could have implications in human breast cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8825133     DOI: 10.1007/bf01806503

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  53 in total

Review 1.  Progestin regulation of cellular proliferation.

Authors:  C L Clarke; R L Sutherland
Journal:  Endocr Rev       Date:  1990-05       Impact factor: 19.871

Review 2.  The p53 tumor suppressor protein, a modulator of cell proliferation.

Authors:  S J Ullrich; C W Anderson; W E Mercer; E Appella
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

3.  Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes.

Authors:  E A Musgrove; C S Lee; R L Sutherland
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

4.  Proliferative and secretory activity in human breast during natural and artificial menstrual cycles.

Authors:  J J Going; T J Anderson; S Battersby; C C MacIntyre
Journal:  Am J Pathol       Date:  1988-01       Impact factor: 4.307

5.  Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor.

Authors:  M F Press; G L Greene
Journal:  Endocrinology       Date:  1988-03       Impact factor: 4.736

6.  The significance of nucleolar organizer region (AgNOR) score in predicting meningioma recurrence.

Authors:  K Kunishio; T Ohmoto; T Matsuhisa; T Maeshiro; T Furuta; K Matsumoto
Journal:  Cancer       Date:  1994-04-15       Impact factor: 6.860

7.  Argyrophilic proteins of the nucleolar organizer region in acute leukemias and its relation to the S-phase fraction of leukemic cells.

Authors:  S Nakamura; Y Takeda; Y Okabe; T Yoshida; S Ohtake; K Kobayashi; M Kanno; T Matsuda
Journal:  Acta Haematol       Date:  1992       Impact factor: 2.195

8.  TGF-beta 1-induced inhibition of mouse mammary ductal growth: developmental specificity and characterization.

Authors:  C W Daniel; G B Silberstein; K Van Horn; P Strickland; S Robinson
Journal:  Dev Biol       Date:  1989-09       Impact factor: 3.582

9.  The expression of progesterone receptors coincides with an arrest of DNA synthesis in human breast cancer.

Authors:  C Ballare; A I Bravo; I Sorin; N Guman; J A Schiaffi; R Yomha; A Bagnati; B Lema; J Mordoh
Journal:  Cancer       Date:  1991-03-01       Impact factor: 6.860

10.  Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation.

Authors:  R I Nicholson; N Bouzubar; K J Walker; R McClelland; A R Dixon; J F Robertson; I O Ellis; R W Blamey
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

View more
  7 in total

1.  Estrogen-induced upregulation of Sftpb requires transcriptional control of neuregulin receptor ErbB4 in mouse lung type II epithelial cells.

Authors:  Katja Zscheppang; Mirja Konrad; Melanie Zischka; Verena Huhn; Christiane E L Dammann
Journal:  Biochim Biophys Acta       Date:  2011-07-08

Review 2.  ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers.

Authors:  Joeli A Brinkman; Dorraya El-Ashry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2009-03-05       Impact factor: 2.673

3.  Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Authors:  Ke-da Yu; Gen-hong Di; Jiong Wu; Jin-song Lu; Kun-wei Shen; Guang-yu Liu; Zhen-zhou Shen; Zhio-ming Shao
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-17       Impact factor: 4.553

4.  Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians.

Authors:  Tulay Koru-Sengul; Ana M Santander; Feng Miao; Lidia G Sanchez; Merce Jorda; Stefan Glück; Tan A Ince; Mehrad Nadji; Zhibin Chen; Manuel L Penichet; Margot P Cleary; Marta Torroella-Kouri
Journal:  Breast Cancer Res Treat       Date:  2016-06-09       Impact factor: 4.872

Review 5.  Molecular markers for predicting response to tamoxifen in breast cancer patients.

Authors:  D R Ciocca; R Elledge
Journal:  Endocrine       Date:  2000-08       Impact factor: 3.925

6.  BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma

Authors:  Mohit Kumar; Ram Krishna Sahu; Aditi Goyal; Sonal Sharma; Navneet Kaur; Ravi Mehrotra; Usha Rani Singh; Suresh Hedau
Journal:  Asian Pac J Cancer Prev       Date:  2017-12-29

7.  Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular stress.

Authors:  Cheng-Yu Lin; Alexandra Beattie; Behzad Baradaran; Eloise Dray; Pascal H G Duijf
Journal:  Sci Rep       Date:  2018-09-17       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.